Aulos Biosciences is now recruiting cancer patients in Australian medical centers for a trial of the world’s first antibody drug designed by a computer.
The computationally designed antibody, known as AU-007, was planned by the artificial intelligence platform of Israeli biotech company Biolojic Design from Rehovot, in a way that would target a protein in the human body known as interleukin-2 (IL-2).
The goal is for the IL-2 pathway to activate the body’s immune system and attack the tumors.
Comments are closed.